EGFR and non-small cell lung carcinoma: Combining PFS of ten trials involving 2205 NSCLC harboring wild-type EGFR produced a significant improvement from the doublet targeted therapy (HR 0.68, 95% CI 0.57-0.83, p < 0.0001; I2 = 64%; Supplementary Figure 4).